

Table S2 The survival of patients in different groups

Histological subtype	Groups	mOS (days)	P-value
LCNEC (Figure 6A)	CD3 ⁺ CD8 ⁺ iTILs presence <i>vs.</i> absence	1309 <i>vs.</i> 272.5	0.0124
LCNEC (Figure 6B)	CD163 ⁺ iTILs high <i>vs.</i> low	1422 <i>vs.</i> 365	0.0638
LCNEC (Figure 6C)	CD163 ⁺ sTILs high <i>vs.</i> low	1422 <i>vs.</i> 420	0.0550
SCLC (Figure 7A)	CD8 ⁺ sTILs high <i>vs.</i> low	NR <i>vs.</i> 548	0.0046
SCLC (Figure 7B)	CD3 ⁺ CD8 ⁺ sTILs high <i>vs.</i> low	NR <i>vs.</i> 548	0.0845
LCNEC (Figure 8A)	CD3 ⁺ CD8 ⁺ index high <i>vs.</i> low	1411 <i>vs.</i> 392.5	0.0340
SCLC (Figure 8B)	CD68 ⁺ CD163 ⁺ index high <i>vs.</i> low	548 <i>vs.</i> NR	0.0410
SCLC (Figure 8C)	CD163 ⁺ index high <i>vs.</i> low	548 <i>vs.</i> NR	0.0410

iTILs: iTILs within cancer cell nests; sTILs: iTILs in cancer stroma; OS: overall survival; LCNEC: large cell neuroendocrine carcinoma; SCLC: small cell lung cancer; iTILs/sTILs index = the positive rate of iTILs/the positive rate of sTILs; NR, not reached; CD: cell differentiation.